[Newsmp] In April, while the pharmaceutical index showed signs of recovery by surpassing the 13,000 mark and climbing up to 14,000, there were significant differences among investors.
According to the Korea Exchange, institutional investors and foreign investors recorded a net buying amount of KRW 301.3 billion and KRW 120.5 billion, for the 47 stocks of the pharmaceutical index in April. However, during the same period, individuals sold a net amount of KRW 423.1 billion worth of shares.
Institutional investors showed significant interest in Celltrion. The net buying amount of Celltrion shares by institutional investors amounted to KRW 179.6 billion, making it the second-largest net purchase after SK Hynix among over 900 listed stocks in the Korean stock market.
Following Celltrion, institutional investors recorded a net purchase amount of KRW 53.9 billion for Yuhan Corporation, KRW 52.3 billion for Hanmi Pharmaceutical, KRW 23.4 billion for SK Bioscience, and KRW 10.1 billion for HanAll Biopharma.
On the other hand, Samsung Biologics was the only stock that institutional investors sold more than KRW 10 billion worth of, with net sales of KRW 11.9 billion.
Foreign investors also showed a similar trend to institutions. They net bought about KRW 69.3 billion of Celltrion, about KRW 33.4 billion of Hanmi Pharmaceutical, about KRW 22.6 billion of HanAll Biopharma, and about KRW 16.1 billion of Yuhan Corporation.
Out of the five stocks that saw net purchases of over KRW 10 billion by institutions, four of them were also net-purchased by foreign investors for over KRW 1 billion, except for SK Bioscience.
SK Bioscience was the only stock in which foreign investors sold more than KRW 10 billion worth of shares in net sales over the past month, and the amount reached KRW 30.4 billion.
On the other hand, the only stock in which individuals purchased a net amount exceeding KRW 10 billion was Samsung Biologics, with a total of KRW 24.9 billion.
Meanwhile, individual investors heavily sold off Celltrion with a net selling of KRW 253.3 billion, while Hanmi Pharmaceutical, Yuhan Corporation, and HanAll Biopharma also saw net selling of KRW 84.4 billion, KRW 68.6 billion, and KRW 31.9 billion respectively.
